PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “SARCOMA, LYMPHOSARCOMA”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources

[Comparative S-adenosyl-L-methionine and S-adenosyl-L-homocysteine content in the tissues of experimental tumors in the process of their growth].

Content of S-adenosyl-l-methionine (SAM) in rat tissues of Pliss lymphosarcoma, of sarcoma 180 and in adenocarcinoma 755 of mice varied within the limits of 27-57 nM/g, 60-64 nM/g and 32-40 nM/g of wet tissue, respectively, content of S-adenosyl-l-homocysteine (SAH) varied in the tumors studied within the limits of 19-28, 16-21 and 11-20 nM/g, respectively. In the tumor bearing mice the content of SAM was unaltered in liver tissue during the growth of sarcoma 180 or adenocarcinoma 755. Development of Pliss lymphosarcoma in rats was accompanied by a decrease in content of SAM in liver tissue. When the rate of Pliss lymphosarcoma growth was decreased, the content of SAH in the tumor was unaltered but the level of SAM was decreased about 2-fold and the ratio SAH/SAM was increased, correspondingly, approximately 2-fold. If the rate of growth of mice adenocarcinoma 755 was elevated, content of SAM in the tumor was increased but the SAH level was markedly decreased and the ratio SAH/SAM was decreased about 2-fold. Concentrations of SAH and SAM were unaltered in mice sarcoma 180 with the linear rate of growth from 0.15 to 1.6 g. The data obtained suggest that the rate of growth of the tumors studied correlated with relative and absolute content of SAM and SAH.

Adenocarcinoma↗

Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): parolonged unmaintained remissions.

High doses of methotrexate (HDMTX), given in pulse infusions of 3 to 30 mg/kg body weight, were studied in 22 children with non-Hodgkin's lymphoma. Sixteen complete and five partial remissions were observed in 21 patients evaluable for remission induction. The dose of MTX was increased stepwise on consecutive treatments until objective tumor response occured. Citrovorum factor rescue (CFR) was used "on demand" when toxicity started to develop, and routinely after 30 mg/kg of MTX. Twelve patients who had no previous chemotherapy were entered in a Phase II study consisting of remission induction with HDMTX and remission maintenance with monthly HDMTX supplemented with one monthly injection of vincristine and Cytoxan and five days of oral 6-mercaptopurine and prednisone. Eleven patients achieved remissions (eight complete and three partial) with HDMTX and one with surgery and radiation followed by HDMTX. The three partial remissions improved to complete remission during remission maintenance. All 12 were given the maintenance cyclic combination chemotherapy. Seven of the 12 patients entered the unmaintained phase of the study. One patient relapsed 6 months after cessation of therapy and died 4 years after diagnosis. Six patients are alive and free of disease 2 1/2 to 5 1/2 years after discountinuing treatment and 4 1/2 to 8 1/3 years after diagnosis. Five of these six patients had advanced (Stage IV) disease.

Child↗